Analytic Report On Baxter International Inc (NYSE:BAX)
Baxter International Inc (NYSE:BAX) through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates in two segments, BioScience and Medical Products. The BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and certain vaccines. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. It also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies; and to treat end-stage renal disease or irreversible kidney failure. In addition, this segment manufactures solutions and other products for peritoneal dialysis, a home-based therapy; and distributes products for hemodialysis, which is generally conducted in a hospital or clinic. The company serves hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients at home under physician supervision in the United States, Europe, the Asia-Pacific, Latin America, and Canada. Baxter International Inc. sells its products through its direct sales force and also to and through independent distributors, drug wholesalers acting as sales agents, and specialty pharmacy or homecare companies. The company was founded in 1931 and is based in Deerfield, Illinois.
Baxter International Inc (NYSE:BAX)
BSX vs. Industry Leaders
Statistic Industry Leaders BAX BAX Ranked
|Market Capitalization||ACL||N/A||30.62B||2 / 157|
|P/E Ratio (ttm)||CSRT.L||1,422.15||14.08||41 / 157|
|PEG Ratio (ttm, 5 yr expected)||YDNT||15.10||1.43||20 / 157|
|Revenue Growth (Qtrly YoY)||TOS.TO||468.00%||2.70%||62 / 157|
|EPS Growth (Qtrly YoY)||BVX||N/A||13.60%||25 / 157|
|Long-Term Growth Rate (5 yr)||ELGX||95.60%||8.43%||52 / 157|
|Return on Equity (ttm)||CPTS||-5.19%||33.12%||5 / 157|
|Long-Term Debt/Equity (mrq)||76.084||N/A|
|Dividend Yield (annual)||KNSY||3.50%||2.50%||4 / 157|
Baxter International Inc (NYSE:BAX) generated the revenue of $3.59 billion for the quarter ended December 31st, 2011 as compared to revenue of $3.49 billion for the same period last year. The company reported the net profit of $463 million or earnings of $1.17 per share for the respective quarter as compared to net income of $423 million or earnings of $1.28 per share last year.
The company’s total assets accumulate up to $19.07 billion out of which fixed assets have the highest proportion. The company maintains a strong short term liquidity position as per its current ratio of 1.78 times.
← Report On Bristol Myers Squibb Co (NYSE:BMY) Healthcare Sector Stock Industry Analysis On Aetna Inc (NYSE:AET) →